BNGO Stock Forecast: BioNano Genomics Inc skyrockets as Saphyr is a winner at the Cytogenics Symposium
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NASDAQ:BNGO surges by 23.45% after regaining NASDAQ compliance.
- BNGO’s Saphyr platform shines at the annual Next-Generation Cytogenics Symposium.
- BNGO has the attention of noted investment firm Ark invest.
NASDAQ:BNGO continued its 2021 momentum as the red-hot genomics sector keeps hitting new highs on a daily basis. On Thursday, small-cap upstart BioNano Genomics caught the eye of value investors as the stock added 23.45% to close the trading session at $6.95, but not before hitting new 52-week highs of $7.95 during intraday hours. Shares are up over 150% already this year and as the COVID-19 pandemic continues to hit our world hard, healthcare and biogenomics are at the forefront of investor interest.
That interest was clear as BioNano Genomics presented its Saphyr platform at the Next-Generaton Cytogenics Symposium this year and impressed medical professionals with its accuracy in detecting tumors, as well as saving doctors time and money without having to run extra costly tests or scans. BNGO also announced that it would be revealing information on how Saphyr can detect genetic drivers that lead to increased susceptibility to COVID-19. The Saphyr platform is able to identify structural variants in our genes that have control over potential immune system responses. The importance of this? Determining why some people react severely to COVID-19, while some remain symptomatic.
BNGO stock price
If all of that is not enough for investors, noted genomics industry investors ARK invest have also apparently been keen to know more about BNGO. ARK investor Simon Barnett was reported to be interested in speaking with BNGO’s CEO Dr. Robert Erik Holmlin late in 2020, so investors are anticipating that BNGO could be added to ARK’s genomics ETF ARK.G at some point in the near future, especially after its impressive showing at the symposium.
- NASDAQ:BNGO surges by 23.45% after regaining NASDAQ compliance.
- BNGO’s Saphyr platform shines at the annual Next-Generation Cytogenics Symposium.
- BNGO has the attention of noted investment firm Ark invest.
NASDAQ:BNGO continued its 2021 momentum as the red-hot genomics sector keeps hitting new highs on a daily basis. On Thursday, small-cap upstart BioNano Genomics caught the eye of value investors as the stock added 23.45% to close the trading session at $6.95, but not before hitting new 52-week highs of $7.95 during intraday hours. Shares are up over 150% already this year and as the COVID-19 pandemic continues to hit our world hard, healthcare and biogenomics are at the forefront of investor interest.
That interest was clear as BioNano Genomics presented its Saphyr platform at the Next-Generaton Cytogenics Symposium this year and impressed medical professionals with its accuracy in detecting tumors, as well as saving doctors time and money without having to run extra costly tests or scans. BNGO also announced that it would be revealing information on how Saphyr can detect genetic drivers that lead to increased susceptibility to COVID-19. The Saphyr platform is able to identify structural variants in our genes that have control over potential immune system responses. The importance of this? Determining why some people react severely to COVID-19, while some remain symptomatic.
BNGO stock price
If all of that is not enough for investors, noted genomics industry investors ARK invest have also apparently been keen to know more about BNGO. ARK investor Simon Barnett was reported to be interested in speaking with BNGO’s CEO Dr. Robert Erik Holmlin late in 2020, so investors are anticipating that BNGO could be added to ARK’s genomics ETF ARK.G at some point in the near future, especially after its impressive showing at the symposium.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.